drugset

drugset / Trial / NCT00108823

The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

NCT00108823 ↗

Phase 3 Completed 550 enrolled AstraZeneca

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.

Timeline

Start: 2004-10
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Roflumilast	Small molecule	500 ug	—

Indications